{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:vonlerolizumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:rocatinlimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
JAN:GOSURANEMAB [JAN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03388593: Phase 3 Interventional Recruiting Chronic Heart Failure
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:cosfroviximab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00418795: Phase 2/Phase 3 Interventional Completed Acute Intermittent Porphyria
(2003)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:amilomotide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:afasevikumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:vanucizumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN